(HOLX) Hologic - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US4364401012
Stock: Diagnostics, Imaging, Surgical, Skeletal
Total Rating 45
Risk 86
Buy Signal -0.29
| Risk 5d forecast | |
|---|---|
| Volatility | 3.01% |
| Relative Tail Risk | -7.32% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.64 |
| Alpha | 15.43 |
| Character TTM | |
|---|---|
| Beta | -0.012 |
| Beta Downside | 0.040 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.85% |
| CAGR/Max DD | -0.05 |
EPS (Earnings per Share)
Revenue
Description: HOLX Hologic March 02, 2026
Hologic, Inc. (NASDAQ: HOLX) develops, manufactures, and supplies a broad portfolio of womens health solutions-including diagnostics, medical imaging, and surgical products-across four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Its offerings range from Aptima molecular assays for infectious diseases and SARS-CoV-2 to 3D digital mammography systems and minimally invasive uterine-fibroid devices.
In its most recent fiscal year (2025), Hologic reported revenue of $5.2 billion, a 7% year-over-year increase driven by strong growth in the Breast Health segment (+9%) and sustained demand for COVID-19 and HPV testing in Diagnostics. The company posted an adjusted EBITDA margin of 22%, reflecting operational efficiencies from its direct-sales model. Industry trends such as the expanding women’s-health market-projected to grow at a 6% CAGR through 2030-and the shift toward outpatient surgical procedures continue to underpin Hologic’s growth outlook.
For deeper insights, you might explore ValueRay’s analysis of HOLX.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income: 543.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -1.89 > 1.0 |
| NWC/Revenue: 70.09% < 20% (prev 61.68%; Δ 8.41% < -1%) |
| CFO/TA 0.12 > 3% & CFO 1.10b > Net Income 543.9m |
| Net Debt (352.3m) to EBITDA (1.01b): 0.35 < 3 |
| Current Ratio: 4.04 > 1.5 & < 3 |
| Outstanding Shares: last quarter (225.9m) vs 12m ago -2.68% < -2% |
| Gross Margin: 52.82% > 18% (prev 0.56%; Δ 5226 % > 0.5%) |
| Asset Turnover: 46.08% > 50% (prev 46.27%; Δ -0.19% > 0%) |
| Interest Coverage Ratio: 8.00 > 6 (EBITDA TTM 1.01b / Interest Expense TTM 95.2m) |
Altman Z'' 4.85
| A: 0.32 (Total Current Assets 3.84b - Total Current Liabilities 951.3m) / Total Assets 9.18b |
| B: 0.39 (Retained Earnings 3.59b / Total Assets 9.18b) |
| C: 0.09 (EBIT TTM 761.8m / Avg Total Assets 8.95b) |
| D: 0.89 (Book Value of Equity 3.50b / Total Liabilities 3.94b) |
| Altman-Z'' Score: 4.85 = AA |
Beneish M -3.12
| DSRI: 0.91 (Receivables 584.2m/631.4m, Revenue 4.13b/4.04b) |
| GMI: 1.06 (GM 52.82% / 55.98%) |
| AQI: 0.97 (AQ_t 0.52 / AQ_t-1 0.54) |
| SGI: 1.02 (Revenue 4.13b / 4.04b) |
| TATA: -0.06 (NI 543.9m - CFO 1.10b) / TA 9.18b) |
| Beneish M-Score: -3.12 (Cap -4..+1) = AA |
What is the price of HOLX shares?
As of March 03, 2026, the stock is trading at USD 75.45 with a total of 1,817,677 shares traded.
Over the past week, the price has changed by +0.01%, over one month by +0.95%, over three months by +0.84% and over the past year by +19.25%.
Over the past week, the price has changed by +0.01%, over one month by +0.95%, over three months by +0.84% and over the past year by +19.25%.
Is HOLX a buy, sell or hold?
Hologic has received a consensus analysts rating of 3.45.
Therefor, it is recommend to hold HOLX.
- StrongBuy: 3
- Buy: 3
- Hold: 14
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the HOLX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 76.6 | 1.5% |
| Analysts Target Price | 76.6 | 1.5% |
HOLX Fundamental Data Overview February 28, 2026
P/E Trailing = 31.2158
P/E Forward = 14.9254
P/S = 4.07
P/B = 3.1192
P/EG = 1.5076
Revenue TTM = 4.13b USD
EBIT TTM = 761.8m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 12.8m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 352.3m USD (from netDebt column, last quarter)
Enterprise Value = 16.95b USD (16.79b + Debt 2.52b - CCE 2.36b)
Interest Coverage Ratio = 8.00 (Ebit TTM 761.8m / Interest Expense TTM 95.2m)
EV/FCF = 16.96x (Enterprise Value 16.95b / FCF TTM 999.6m)
FCF Yield = 5.90% (FCF TTM 999.6m / Enterprise Value 16.95b)
FCF Margin = 24.22% (FCF TTM 999.6m / Revenue TTM 4.13b)
Net Margin = 13.18% (Net Income TTM 543.9m / Revenue TTM 4.13b)
Gross Margin = 52.82% ((Revenue TTM 4.13b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 55.96% (prev 60.90%)
Tobins Q-Ratio = 1.85 (Enterprise Value 16.95b / Total Assets 9.18b)
Interest Expense / Debt = 1.10% (Interest Expense 27.6m / Debt 2.52b)
Taxrate = 22.03% (50.6m / 229.7m)
NOPAT = 594.0m (EBIT 761.8m * (1 - 22.03%))
Current Ratio = 4.04 (Total Current Assets 3.84b / Total Current Liabilities 951.3m)
Debt / Equity = 0.48 (Debt 2.52b / totalStockholderEquity, last quarter 5.25b)
Debt / EBITDA = 0.35 (Net Debt 352.3m / EBITDA 1.01b)
Debt / FCF = 0.35 (Net Debt 352.3m / FCF TTM 999.6m)
Total Stockholder Equity = 4.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 543.9m / Total Assets 9.18b)
RoE = 11.01% (Net Income TTM 543.9m / Total Stockholder Equity 4.94b)
RoCE = 10.24% (EBIT 761.8m / Capital Employed (Equity 4.94b + L.T.Debt 2.50b))
RoIC = 7.97% (NOPAT 594.0m / Invested Capital 7.45b)
WACC = 5.22% (E(16.79b)/V(19.32b) * Re(5.87%) + D(2.52b)/V(19.32b) * Rd(1.10%) * (1-Tc(0.22)))
Discount Rate = 5.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.03%
[DCF] Terminal Value 85.53% ; FCFF base≈1.05b ; Y1≈968.1m ; Y5≈878.3m
[DCF] Fair Price = 116.9 (EV 26.45b - Net Debt 352.3m = Equity 26.09b / Shares 223.2m; r=5.90% [WACC]; 5y FCF grow -9.37% → 2.90% )
EPS Correlation: -16.25 | EPS CAGR: -16.77% | SUE: -3.25 | # QB: 0
Revenue Correlation: -27.58 | Revenue CAGR: -8.06% | SUE: -3.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.11 | Chg7d=-0.009 | Chg30d=-0.047 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-09-30): EPS=4.42 | Chg7d=+0.000 | Chg30d=-0.135 | Revisions Net=-8 | Growth EPS=+3.8% | Growth Revenue=+3.4%
EPS next Year (2027-09-30): EPS=3.78 | Chg7d=+0.000 | Chg30d=-0.230 | Revisions Net=-5 | Growth EPS=+15.4% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = -1.5% (Analyst 3.2% - Implied 4.7%)
P/E Forward = 14.9254
P/S = 4.07
P/B = 3.1192
P/EG = 1.5076
Revenue TTM = 4.13b USD
EBIT TTM = 761.8m USD
EBITDA TTM = 1.01b USD
Long Term Debt = 2.50b USD (from longTermDebt, last quarter)
Short Term Debt = 12.8m USD (from shortTermDebt, last quarter)
Debt = 2.52b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 352.3m USD (from netDebt column, last quarter)
Enterprise Value = 16.95b USD (16.79b + Debt 2.52b - CCE 2.36b)
Interest Coverage Ratio = 8.00 (Ebit TTM 761.8m / Interest Expense TTM 95.2m)
EV/FCF = 16.96x (Enterprise Value 16.95b / FCF TTM 999.6m)
FCF Yield = 5.90% (FCF TTM 999.6m / Enterprise Value 16.95b)
FCF Margin = 24.22% (FCF TTM 999.6m / Revenue TTM 4.13b)
Net Margin = 13.18% (Net Income TTM 543.9m / Revenue TTM 4.13b)
Gross Margin = 52.82% ((Revenue TTM 4.13b - Cost of Revenue TTM 1.95b) / Revenue TTM)
Gross Margin QoQ = 55.96% (prev 60.90%)
Tobins Q-Ratio = 1.85 (Enterprise Value 16.95b / Total Assets 9.18b)
Interest Expense / Debt = 1.10% (Interest Expense 27.6m / Debt 2.52b)
Taxrate = 22.03% (50.6m / 229.7m)
NOPAT = 594.0m (EBIT 761.8m * (1 - 22.03%))
Current Ratio = 4.04 (Total Current Assets 3.84b / Total Current Liabilities 951.3m)
Debt / Equity = 0.48 (Debt 2.52b / totalStockholderEquity, last quarter 5.25b)
Debt / EBITDA = 0.35 (Net Debt 352.3m / EBITDA 1.01b)
Debt / FCF = 0.35 (Net Debt 352.3m / FCF TTM 999.6m)
Total Stockholder Equity = 4.94b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.07% (Net Income 543.9m / Total Assets 9.18b)
RoE = 11.01% (Net Income TTM 543.9m / Total Stockholder Equity 4.94b)
RoCE = 10.24% (EBIT 761.8m / Capital Employed (Equity 4.94b + L.T.Debt 2.50b))
RoIC = 7.97% (NOPAT 594.0m / Invested Capital 7.45b)
WACC = 5.22% (E(16.79b)/V(19.32b) * Re(5.87%) + D(2.52b)/V(19.32b) * Rd(1.10%) * (1-Tc(0.22)))
Discount Rate = 5.87% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -3.03%
[DCF] Terminal Value 85.53% ; FCFF base≈1.05b ; Y1≈968.1m ; Y5≈878.3m
[DCF] Fair Price = 116.9 (EV 26.45b - Net Debt 352.3m = Equity 26.09b / Shares 223.2m; r=5.90% [WACC]; 5y FCF grow -9.37% → 2.90% )
EPS Correlation: -16.25 | EPS CAGR: -16.77% | SUE: -3.25 | # QB: 0
Revenue Correlation: -27.58 | Revenue CAGR: -8.06% | SUE: -3.01 | # QB: 0
EPS next Quarter (2026-06-30): EPS=1.11 | Chg7d=-0.009 | Chg30d=-0.047 | Revisions Net=-2 | Analysts=8
EPS current Year (2026-09-30): EPS=4.42 | Chg7d=+0.000 | Chg30d=-0.135 | Revisions Net=-8 | Growth EPS=+3.8% | Growth Revenue=+3.4%
EPS next Year (2027-09-30): EPS=3.78 | Chg7d=+0.000 | Chg30d=-0.230 | Revisions Net=-5 | Growth EPS=+15.4% | Growth Revenue=+5.2%
[Analyst] Revisions Ratio: -0.50 (1 Up / 3 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 4.7% (Discount Rate 7.9% - Earnings Yield 3.2%)
[Growth] Growth Spread = -1.5% (Analyst 3.2% - Implied 4.7%)